GlassScriptPhysician profile
Puja Goswami
NPI 1912168857
$2,977.71
in general payments reported to CMS, 2019-2025
25 companies · $538 in 2025
The $538 reported for 2025 was more than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
See the full distribution for Nephrology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $475 · 2020: $142 · 2021: $13.08 · 2022: $536 · 2023: $438 · 2024: $835 · 2025: $538.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,811.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,810.97 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $661.35 | 2019-2024 | Farxiga, Lokelma |
| Otsuka America Pharmaceutical, INC. | $211.95 | 2019-2025 | Jynarque, Voyxact |
| Bayer Healthcare Pharmaceuticals INC. | $191.67 | 2022-2025 | |
| Akebia Therapeutics INC | $157.13 | 2019-2022 | |
| Opko Pharmaceuticals, LLC | $148.38 | 2022-2024 | Rayaldee |
| Daiichi Sankyo INC. | $143.42 | 2022-2025 | Injectafer |
| Amgen INC. | $128.51 | 2024-2025 | Krystexxa, Tavneos |
| Travere Therapeutics, INC. | $126.54 | 2023-2025 | |
| Baxter Healthcare | $125.00 | 2022 | |
| Vifor Pharma, INC. | $122.43 | 2019-2023 | Veltassa, Korsuva |
| Calliditas Therapeutics US INC. | $112.13 | 2024-2025 | Tarpeyo |
| Mallinckrodt Hospital Products INC. | $109.59 | 2020-2025 | Acthar |
| Novo Nordisk INC | $102.82 | 2024-2025 | Ozempic, Rybelsus |
| Ani Pharmaceuticals, INC. | $86.96 | 2024 | Purified Cortrophin Gel |
| Boehringer Ingelheim Pharmaceuticals, INC. | $83.86 | 2023-2024 | Jardiance |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $80.13 | 2025 | |
| Lilly USA, LLC | $78.66 | 2023-2025 | Jardiance |
| Ardelyx, INC. | $69.17 | 2024-2025 | Ibsrela |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $61.37 | 2022-2023 | Jynarque |
| Aurinia Pharma U.S., INC. | $59.11 | 2022-2023 | Lupkynis |
| Abiomed | $36.79 | 2023 | Impella |
| Impulse Dynamics (USA) INC. | $26.19 | 2022 | |
| Fresenius USA Marketing, INC. | $24.92 | 2024 | Velphoro |
| Glaxosmithkline, LLC. | $17.64 | 2022 | |
| Hikma Pharmaceuticals USA | $11.99 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Puja Goswami listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.